70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age-Reference-Cited by-同舟云学术

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Published:2021-04 Issue:4 Volume:22 Page:476-488
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Piccart Martine,van 't Veer Laura J,Poncet Coralie,Lopes Cardozo Josephine M N,Delaloge Suzette,Pierga Jean-Yves,Vuylsteke Peter,Brain Etienne,Vrijaldenhoven Suzan,Neijenhuis Peter A,Causeret Sylvian,Smilde Tineke J,Viale Giuseppe,Glas Annuska M,Delorenzi Mauro,Sotiriou Christos,Rubio Isabel T,Kümmel Sherko,Zoppoli Gabriele,Thompson Alastair M,Matos Erika,Zaman Khalil,Hilbers Florentine,Fumagalli Debora,Ravdin Peter,Knox Susan,Tryfonidis Konstantinos,Peric Aleksandra,Meulemans Bart,Bogaerts Jan,Cardoso Fatima,Rutgers Emiel J T

Funder

European Organisation for Research and Treatment of Cancer

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. International web-based consultation on priorities for translational breast cancer research;Dowsett;Breast Cancer Res,2007

3. Long-term toxic effects of adjuvant chemotherapy in breast cancer;Azim;Ann Oncol,2011

4. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis;Ferreira;Ann Oncol,2019

5. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer;Sparano;N Engl J Med,2018

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

2. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

3. The application of lung immune prognostic index in predicting the prognosis of 302 STS patients;Frontiers in Oncology;2024-09-09

4. Optimal management of breast cancer with physical exam negative/radiological abnormal axilla;Scientific Reports;2024-09-03

5. Hormone receptor-positive early breast cancer in young women: A comprehensive review;Cancer Treatment Reviews;2024-09